



May 23, 2018

J-Pharma Co., Ltd.

JPH203 Phase I result will be presented at ASCO Annual Meeting

American Society of Clinical Oncology selected “First-in-human Phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors” to be presented at its Annual Meeting scheduled at Chicago June 1 – 5 2018 and Dr. Naohiro Okano, M.D. Assistant Professor, Department of Internal Medicine, Medical Oncology School of Medicine Kyorin University (Professor Dr. Junji Furuse) will report the result at the Poster Discussion Session.

- Title: First-in-human phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors.
- Poster Board: #345
- Abstract Number: 2519
- Poster Discussion Session: Monday, June 4, 2018, 3:00 PM - 4:15 PM
- Venue: South Building #406, McCormick Place, Chicago, IL, USA
(<http://www.mccormickplace.com/index.php>)

The initial report was made at ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) held on January 19, 2018 and the report is included in our News & Topics as “Completion of Phase I clinical trial of novel anti-cancer agent JPH 203 (http://www.j-pharma.com/assets/images/pressrelease_20180119_e.pdf)”

Our Executive Chairman Dr. Hitoshi Endou, M.D., Ph.D. and President & CEO Mr. Takeshi Hirayama will also attend the meeting.

=====